Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Observational Prospective Study on Patients Treated With Norditropin®
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21249
- Registration Number
- NCT00960128
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
Comparison of Repaglinide and Metformin Combination Tablet Versus Repaglinide and Metformin as Separate Tablets in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-14
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT00959101
Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT00956345
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom
A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 38
- Registration Number
- NCT00951873
Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00951405
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom
Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21
- Registration Number
- NCT00943501
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 31
- Registration Number
- NCT00936403
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Cambridge, United Kingdom
An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 121
- Registration Number
- NCT00934063
A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin
Phase 1
Completed
- Conditions
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 86
- Registration Number
- NCT00931476
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Honolulu, Hawaii, United States
Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 8
- Registration Number
- NCT00922792
© Copyright 2024. All Rights Reserved by MedPath